# Interpace Fundamentals

Interpace Biosciences fundamentals help investors to digest information that contributes to Interpace Biosciences' financial success or failures. It also enables traders to predict the movement of Interpace OTC Stock. The fundamental analysis module provides a way to measure Interpace Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Interpace Biosciences otc stock.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Interpace | Select Account or Indicator |

**K**, whereas Earning Before Interest and Taxes EBIT is forecasted to decline to (16.3

**M**).

## Interpace Book Value Per Share Analysis

Interpace Biosciences' Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.## Interpace Biosciences Book Value per Share | ## (10.53) |

Book Value per Share | = | Common Equity Average Shares |

## Current Interpace Biosciences Book Value Per Share | 0.42 X |

Most of Interpace Biosciences' fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Interpace Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

## Interpace Book Value Per Share Historical Pattern

Today, most investors in Interpace Biosciences OTC Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Interpace Biosciences' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's book value per share growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Interpace Biosciences book value per share as a starting point in their analysis.

Interpace Biosciences Book Value Per Share |

Share

Timeline |

The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.

Compare to competition |

## Interpace Shareholders Equity

## Shareholders Equity | ## 43.92 Million |

In accordance with the recently published financial statements, the book value per share of Interpace Biosciences is about 0.419 times. This is 124.65% lower than that of the Health Care Providers & Services sector and 100.42% lower than that of the Health Care industry. The book value per share for all United States stocks is 99.98% higher than that of the company.

## Interpace Biosciences Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Interpace Biosciences's current stock value. Our valuation model uses many indicators to compare Interpace Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Interpace Biosciences competition to find correlations between indicators driving Interpace Biosciences's intrinsic value. More Info.Interpace Biosciences is currently regarded as number one stock in debt to equity category among related companies. It is rated**fifth**overall in price to earning category among related companies . As of December 5, 2022, Price to Earnings Ratio is expected to decline to -2.23. In addition to that, Earnings Before Interest Taxes and Depreciation Amortization EBITDA is expected to decline to about (32.5

**M**). Comparative valuation analysis is a catch-all model that can be used if you cannot value Interpace Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Interpace Biosciences' OTC Stock . Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Interpace Biosciences' earnings, one of the primary drivers of an investment's value.

## Interpace Shares Outstanding Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Interpace Biosciences' direct or indirect competition against its Shares Outstanding to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Interpace Biosciences could also be used in its relative valuation, which is a method of valuing Interpace Biosciences by comparing valuation metrics of similar companies.Interpace Biosciences is currently under evaluation in shares outstanding category among related companies.

## Interpace Biosciences Current Valuation Drivers

We derive many important indicators used in calculating different scores of Interpace Biosciences from analyzing Interpace Biosciences' financial statements. These drivers represent accounts that assess Interpace Biosciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Interpace Biosciences' important valuation drivers and their relationship over time.

2017 | 2018 | 2019 | 2020 | 2021 | 2022 (projected) | ||

Net Income Per Employee | (136.22 K) | (162.88 K) | (136.96 K) | (150.15 K) | (172.68 K) | (186.31 K) | |

Revenue Per Employee | 213.92 K | 211.96 K | 246.02 K | 135.28 K | 121.75 K | 132.3 K | |

Average Assets | 51.18 M | 46.35 M | 57.73 M | 54.44 M | 41.44 M | 51.19 M | |

Earnings Before Interest Taxes and Depreciation Amortization EBITDA | (5.93 M) | (12.3 M) | (11.66 M) | (26.17 M) | (30.09 M) | (32.47 M) | |

Earnings Before Interest Taxes and Depreciation Amortization USD | (8.49 M) | (8.55 M) | (21.8 M) | (20.35 M) | (9.74 M) | (10.51 M) | |

Earnings before Tax | (12.61 M) | (12.69 M) | (26.77 M) | (26.4 M) | (15.61 M) | (16.84 M) | |

Average Equity | 34.29 M | 32.45 M | 21.43 M | (19.48 M) | (37.44 M) | (38.42 M) | |

Enterprise Value | 15.68 M | 14.87 M | 23.28 M | 4.92 M | 38.78 M | 41.84 M | |

Free Cash Flow | (15.29 M) | (9.12 M) | (19.07 M) | (15.55 M) | (9.03 M) | (9.75 M) | |

Invested Capital | (2.8 M) | 3.85 M | 13.24 M | 7.83 M | 16.31 M | 17.59 M | |

Invested Capital Average | (4.2 M) | 2.51 M | 12.24 M | 11.56 M | 11.06 M | 11.93 M | |

Market Capitalization | 27.39 M | 22.88 M | 19.1 M | 12.69 M | 31.18 M | 33.16 M | |

Tangible Asset Value | 20.49 M | 18.59 M | 27.26 M | 25.9 M | 22.71 M | 28.4 M | |

Working Capital | 11.72 M | 9.05 M | (782 K) | (4.11 M) | (3.52 M) | (3.61 M) |

## Interpace Fundamentals

Return On Equity | (2.85) % | |||

Return On Asset | (0.26) % | |||

Profit Margin | (0.59) % | |||

Operating Margin | (0.28) % | |||

Current Valuation | 14.07 M | |||

Shares Outstanding | 4.27 M | |||

Shares Owned by Insiders | 28.12 % | |||

Number of Shares Shorted | 47.35 K | |||

Price to Earning | (1.07) X | |||

Price to Book | 10.04 X | |||

Price to Sales | 0.12 X | |||

Revenue | 41.31 M | |||

Gross Profit | 17.95 M | |||

EBITDA | (9.12 M) | |||

Net Income | (14.94 M) | |||

Cash and Equivalents | 1.86 M | |||

Cash per Share | 0.44 X | |||

Total Debt | 9.44 M | |||

Debt to Equity | 6.55 % | |||

Current Ratio | 0.61 X | |||

Book Value Per Share | 0.42 X | |||

Cash Flow from Operations | (8.72 M) | |||

Short Ratio | 0.19 X | |||

Earnings Per Share | (3.12) X | |||

Target Price | 11.0 | |||

Number of Employees | 147 | |||

Beta | 0.79 | |||

Market Capitalization | 4.91 M | |||

Total Asset | 38.43 M | |||

Retained Earnings | (172.59 M) | |||

Working Capital | (4.21 M) | |||

Current Asset | 19.16 M | |||

Current Liabilities | 23.37 M | |||

Z Score | -2.8 | |||

Net Asset | 38.43 M |

## About Interpace Biosciences Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Interpace Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Interpace Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Interpace Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.Last Reported | Projected for 2022 | ||

Deferred Revenue | 6.6 M | 8.8 M | |

Cost of Revenue | 23.4 M | 29.2 M | |

Revenues | 27.7 M | 28.4 M | |

Revenue to Assets | 0.40 | 0.41 | |

Revenue Per Employee | 121.7 K | 132.3 K |

## Be your own money manager

Our tools can tell you how much better you can do entering a position in Interpace Biosciences without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.## Did you try this?

### Run Sync Your Broker Now

## Sync Your BrokerSync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |

All Next | Launch Module |

## Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Interpace Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.## Build Optimal Portfolios

### Align your risk with return expectations

Please see Interpace Biosciences Piotroski F Score and Interpace Biosciences Altman Z Score analysis. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

## Complementary Tools for analysis

When running Interpace Biosciences price analysis, check to measure Interpace Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Interpace Biosciences is operating at the current time. Most of Interpace Biosciences' value examination focuses on studying past and present price action to predict the probability of Interpace Biosciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Interpace Biosciences' price. Additionally, you may evaluate how the addition of Interpace Biosciences to your portfolios can decrease your overall portfolio volatility.

Transaction HistoryView history of all your transactions and understand their impact on performance | Go | |

Portfolio DiagnosticsUse generated alerts and portfolio events aggregator to diagnose current holdings | Go | |

Probability Of BankruptcyGet analysis of equity chance of financial distress in the next 2 years | Go | |

Options AnalysisAnalyze and evaluate options and option chains as a potential hedge for your portfolios | Go | |

Earnings CallsCheck upcoming earnings announcements updated hourly across public exchanges | Go | |

Portfolio ComparatorCompare the composition, asset allocations and performance of any two portfolios in your account | Go | |

Commodity Channel IndexUse Commodity Channel Index to analyze current equity momentum | Go |